Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.

• Status: Completed
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Endothelial Growth Factors; Ranibizumab

Criteria

Key Inclusion Criteria:

• Diagnosis of active CNV secondary to any causes with the CNV or its sequelae affecting the fovea;

• BCVA must be between ≥ 24 and ≤ 83 letters in the study eye;

• Visual loss in the study eye should mainly be due to the presence of any eligible types of CNV;

Key Exclusion Criteria:

• Women of child-bearing potential;

• Active malignancies;

• History of stroke less than 6 months prior to screening;

• Uncontrolled systemic inflammation or infection;

• Active diabetic retinopathy, active ocular/periocular infectious disease or active severe intra-ocular inflammation;

• CNV- conditions with a high likelihood of spontaneous resolution;

• History of intravitreal treatment with steroids;

• History of laser photocoagulation;

• History of intraocular treatment with any anti-angiogenic drugs.